Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.

Diefenbach CS, Shah Z, Iasonos A, Barakat RR, Levine DA, Aghajanian C, Sabbatini P, Hensley ML, Konner J, Tew W, Spriggs D, Fleisher M, Thaler H, Dupont J.

Gynecol Oncol. 2007 Feb;104(2):435-42. Epub 2006 Oct 4.

PMID:
17023034
2.

Early detection and prognosis of ovarian cancer using serum YKL-40.

Dupont J, Tanwar MK, Thaler HT, Fleisher M, Kauff N, Hensley ML, Sabbatini P, Anderson S, Aghajanian C, Holland EC, Spriggs DR.

J Clin Oncol. 2004 Aug 15;22(16):3330-9.

PMID:
15310777
3.

Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer.

Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, Koçtürk S, Koyuncuoğlu M, Saygılı U.

Gynecol Oncol. 2016 Jan;140(1):64-9. doi: 10.1016/j.ygyno.2015.11.020. Epub 2015 Nov 23.

PMID:
26607777
4.

The diagnostic and prognostic value of serum YKL-40 in endometrial cancer.

Fan JT, Si XH, Liao Y, Shen P.

Arch Gynecol Obstet. 2013 Jan;287(1):111-5. doi: 10.1007/s00404-012-2546-5. Epub 2012 Sep 4.

PMID:
22945838
5.

Serum and tissue level of YKL-40 in endometrial cancer.

Fan JT, Li MJ, Shen P, Xu H, Li DH, Yan HQ.

Eur J Gynaecol Oncol. 2014;35(3):304-8.

PMID:
24984547
6.

The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer.

Zou L, He X, Zhang JW.

Braz J Med Biol Res. 2010 Dec;43(12):1232-8. Epub 2010 Nov 26.

7.

Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.

Dehn H, Høgdall EV, Johansen JS, Jørgensen M, Price PA, Engelholm SA, Høgdall CK.

Acta Obstet Gynecol Scand. 2003 Mar;82(3):287-93.

PMID:
12694127
8.

Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.

Jiang T, Huang L, Zhang S.

BMC Cancer. 2015 May 12;15:396. doi: 10.1186/s12885-015-1260-7.

9.

Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.

Chudecka-Głaz AM, Cymbaluk-Płoska AA, Menkiszak JL, Sompolska-Rzechuła AM, Tołoczko-Grabarek AI, Rzepka-Górska IA.

J Ovarian Res. 2014 Jun 10;7:62. doi: 10.1186/1757-2215-7-62. eCollection 2014.

10.

YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH.

BMC Cancer. 2009 Jan 9;9:8. doi: 10.1186/1471-2407-9-8.

11.

Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.

Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E.

Cancer. 2010 Sep 1;116(17):4114-21. doi: 10.1002/cncr.25196.

12.

Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.

Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H.

J Clin Oncol. 2006 Feb 10;24(5):798-804. Epub 2006 Jan 3.

PMID:
16391295
13.

YKL-40 protein levels and clinical outcome of human endometrial cancer.

Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X.

J Int Med Res. 2010 Jul-Aug;38(4):1448-57.

PMID:
20926018
14.

Serum YKL-40 as a marker for cervical adenocarcinoma.

Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M.

Ann Oncol. 2009 Jan;20(1):71-7. doi: 10.1093/annonc/mdn552. Epub 2008 Aug 22.

PMID:
18723551
15.

High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.

Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E.

Int J Cancer. 2008 Feb 15;122(4):857-63.

16.

Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.

Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C.

Adv Ther. 2008 Aug;25(8):801-9. doi: 10.1007/s12325-008-0082-2.

PMID:
18670741
17.

Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.

Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H.

Cancer. 2006 Mar 1;106(5):1130-9. Erratum in: Cancer. 2006;107(9 No 1):2315.

18.

High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.

Høgdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Høgdall CK.

Oncol Rep. 2003 Sep-Oct;10(5):1535-8.

PMID:
12883737
19.

High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.

Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL.

Breast Cancer Res Treat. 2003 Jul;80(1):15-21.

PMID:
12889595
20.

Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).

Gronlund B, Høgdall EV, Christensen IJ, Johansen JS, Nørgaard-Pedersen B, Engelholm SA, Høgdall C.

Int J Biol Markers. 2006 Jul-Sep;21(3):141-8.

PMID:
17013795

Supplemental Content

Support Center